HIV, Lymphoma
Conditions
Brief summary
The study's chief objective is to observe the evolution of cellular (in terms of expression of transmembrane transporters and their transcriptional regulators) and viral resistance (in terms of development of mutations in the HIV genome that may confer resistance to future treatment for HIV) in HIV-infected patients with lymphoma.
Detailed description
The study team will take two or three tubes of blood on three occasions during the course of chemotherapy. The total amount of blood required for this research project is 64mL (approximately 4 tablespoons). This will allow better understanding of the changes that take place in the blood and the HIV virus itself. It is hoped that this will provide new insights that may aid the understanding and treatment of HIV patients with lymphoma.
Interventions
None listed
Sponsors
St Stephens Aids Trust
Study design
Observational model
CASE_CONTROL
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* The ability to understand and sign a written informed consent form, prior to participation in any screening procedure and must be willing to comply with all study requirements. * Documented HIV-1 infection. * Diagnosis of lymphoma (with the exclusion of the five subjects that will be controls). * On cART or about to start cART as part of clinical routine care before the initiation of chemotherapy.
Exclusion criteria
\- Receiving anti-tuberculosis treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of multi-drug resistance (in terms of expression of transmembrane transporters and their transcriptional regulators) in HIV-infected patients with lymphoma. | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Development of mutations in the HIV genome that may confer resistance to future treatment for HIV. | 3 years |
Countries
United Kingdom
Contacts
Primary ContactMarta Boffito, Dr
Outcome results
None listed